Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Phase 3positiveHETLIOZ®Positive

AI Analysis

Summary

Vanda Pharmaceuticals announced positive Phase 3 results for HETLIOZ® (tasimelteon) in Delayed Sleep-Wake Phase Disorder, meeting its primary endpoint with sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022).

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Primary endpoint met: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022). 60% of HETLIOZ® treated participants shifted sleep at least 30 minutes earlier versus 15% of placebo arm.

Importance:7/10

Sentiment:

0.85

Phase 3positive datasleep disorderprimary endpoint met

Related Companies

$VNDA

Read the original article

Published by PR Newswire Biotech on September 29, 2026 10:45 PM

Read Original